Jul 24, 2024 8:30am EDT Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study
Jun 20, 2024 8:30am EDT Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds